J. Goldman & Co LP Purchases Shares of 181,174 Travere Therapeutics, Inc. (NASDAQ:TVTX)

J. Goldman & Co LP acquired a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 181,174 shares of the company’s stock, valued at approximately $3,156,000.

Other large investors have also modified their holdings of the company. Entropy Technologies LP bought a new stake in shares of Travere Therapeutics during the 4th quarter worth $214,000. US Bancorp DE boosted its position in shares of Travere Therapeutics by 323.4% in the fourth quarter. US Bancorp DE now owns 31,795 shares of the company’s stock worth $554,000 after buying an additional 24,286 shares during the period. Swiss National Bank boosted its position in shares of Travere Therapeutics by 12.8% in the fourth quarter. Swiss National Bank now owns 151,900 shares of the company’s stock worth $2,646,000 after buying an additional 17,200 shares during the period. Jennison Associates LLC acquired a new stake in shares of Travere Therapeutics in the fourth quarter worth $14,222,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Travere Therapeutics in the fourth quarter worth $583,000.

Travere Therapeutics Stock Down 2.1%

NASDAQ:TVTX opened at $20.02 on Monday. The stock’s fifty day moving average price is $18.07 and its two-hundred day moving average price is $18.83. Travere Therapeutics, Inc. has a 52-week low of $6.01 and a 52-week high of $25.29. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -4.88 and a beta of 0.88.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm had revenue of $81.73 million for the quarter, compared to the consensus estimate of $77.44 million. During the same quarter in the prior year, the business earned ($1.76) EPS. The business’s revenue for the quarter was up 83.3% compared to the same quarter last year. On average, analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TVTX shares. Guggenheim reissued a “buy” rating and set a $47.00 price objective on shares of Travere Therapeutics in a research report on Monday, April 14th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Travere Therapeutics in a research report on Friday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research report on Wednesday, April 23rd. Canaccord Genuity Group boosted their price target on Travere Therapeutics from $45.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, April 10th. Finally, Stifel Nicolaus boosted their price objective on Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.79.

Insiders Place Their Bets

In other Travere Therapeutics news, SVP William E. Rote sold 5,200 shares of the company’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total transaction of $122,356.00. Following the transaction, the senior vice president now owns 98,519 shares of the company’s stock, valued at approximately $2,318,152.07. This represents a 5.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Heerma sold 3,074 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $76,850.00. Following the transaction, the insider now directly owns 127,634 shares in the company, valued at approximately $3,190,850. This represents a 2.35% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 96,420 shares of company stock valued at $2,302,575. 4.19% of the stock is currently owned by corporate insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.